Effects of tumour mass and circulating antigen on the biodistribution of111In-labelled F(abâ˛)2 fragments of human prostatic acid phosphatase monoclonal antibody in nude mice bearing PC-82 human prostatic tumour xenografts
- 1 May 1991
- journal article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 18  (5) , 339-345
- https://doi.org/10.1007/bf02285462
Abstract
We have evaluated the effects of tumour mass and circulating antigen (prostatic acid phosphatase, PAP) on the biodistribution and the incorporation of111In-labelled F(abâ˛)2 monoclonal antibody (MoAb) fragments directed against human PAP into human prostatic tumours (PC-82; 0.1â8.9 g) growing in nude mice. The radioactivities in the blood, liver, spleen, kidney and tumour were compared at 1, 3, 4 and 6 days after the intravenous administration of the antibody fragments. There was a significant correlation between the tumour size and the serum PAP concentration in the model employed. Even tissue of a small tumour (< 0.1 g) had a high concentration of PAP, but it was not secreted into the circulation in detectable amounts when measured by radioimmunoassay (the lowest standard was 0.5 Îźg/l). The percentage uptake by tumours of the injected dose per gram of tissue (%ID/g) was inversely proportional to the tumour size at 24 h after the administration of111In-labelled F(abâ˛)2 fragments. This relationship had levelled off by 72 h and most likely reflected a better vascularisation of the smaller tumours. Our results show that the increase in tumour size and in the concentration of circulating antigen in the blood led to decreased tumour-to-blood ratios, since there was a tendency for higher blood activities in mice with larger tumours and higher serum PAP concentrations. There was no correlation between tumour size and label uptake by the liver during the follow-up over 144 h, although serum PAP concentrations ranged from 3.1 Îźg/l to 352 Îźg/l. On the other hand, when compared with our previous data obtained with non-tumour-bearing mice, there was a significant increase in the uptake by the liver and spleen. These results indicate that even a small concentration of circulating antigen was able to trigger an abnormal change in the biodistribution of MoAbs.Keywords
This publication has 29 references indexed in Scilit:
- Biodistribution in normal mice of an111in-labelled prostatic acid phosphatase-specific antibody and its F(ab?)2 fragments derivatized site-specifically or via bicyclic diethyl enetriaminepentaacetic acid anhydrideEuropean Journal of Nuclear Medicine and Molecular Imaging, 1990
- Imaging of colorectal carcinoma with radiolabeled antibodiesSeminars in Nuclear Medicine, 1989
- Radiolabeled monoclonal antibodies in the diagnosis and treatment of malignant melanomaSeminars in Nuclear Medicine, 1989
- Influence of circulating antigen on the biodistribution and tumour localization of radiolabelled monoclonal antibody in a human tumour: Nude mouse xenograft modelEuropean Journal of Cancer and Clinical Oncology, 1989
- Purification of monoclonal antibodies raised against prostate-specific acid phosphatase for use in vivo in radioimaging of prostatic cancerJournal of Immunological Methods, 1989
- Preparation of F(abâ˛)2 fragments from monoclonal mouse IgG1 suitable for use in radioimagingJournal of Immunological Methods, 1988
- The use of steroidâcontaining silastic implants in male nude mice: Plasma hormone levels and the effect of implantation on the weights of the ventral prostate and seminal vesiclesThe Prostate, 1984
- Preparation of F(abâ˛)2 fragments from mouse IgG of various subclassesJournal of Immunological Methods, 1983
- Use of radiolabelled monoclonal anti-CEA antibodies for the detection of human carcinomas by external photoscanning and tomoscintigraphyImmunology Today, 1981
- Assay of estosterone progesterone and 17Îą-hydroxyprogesterone in human plasma by radioimmunoassay after separation on hydroxyalkoxypropyl sephadeJournal of Steroid Biochemistry, 1974